Equity Overview
Price & Market Data
Price: $0.0254
Daily Change: -$0.0₃2 / 0.79%
Range: $0.0254 - $0.0271
Market Cap: $9,804,570
Volume: 29,000
Performance Metrics
1 Week: 8.32%
1 Month: 8.32%
3 Months: -18.80%
6 Months: -27.98%
1 Year: -33.14%
YTD: -20.82%
Company Details
Employees: 18
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.